Publications by authors named "C Feliciani"
Article Synopsis
- The Italian Melanoma Intergroup has launched MelaMEd, an online training program for general practitioners focusing on the prevention and detection of cutaneous melanoma.
- The project involves a pre-training questionnaire to assess participants’ baseline knowledge, which is compared to their post-training responses after completing the course by December 2023.
- Preliminary analysis from January to July 2023 reveals that out of 1320 participants, many recognized key melanoma concepts, but knowledge gaps exist, particularly in specific melanoma recognition rules and management accuracy rates for various skin lesions.
Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study.
J Eur Acad Dermatol Venereol
September 2024
Background: Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases 1 and 2, has been recently approved to treat alopecia areata.
Materials And Methods: We conducted a retrospective study involving 23 medical centres across Italy, enrolling patients affected by severe alopecia areata (SALT >50), for more than 6 months.
Article Synopsis
- A 39-year-old woman with Noonan Syndrome and a RAF1 mutation presented with itchy lesions on her limbs that developed two months prior, characterized by multiple dome-shaped papules.
- Blood tests showed no abnormalities, but a skin biopsy revealed features consistent with Kyrle's disease, a type of perforating dermatosis.
- The patient was treated with narrowband UVB phototherapy, resulting in complete resolution of symptoms despite leaving residual atrophic scars.
Background: Alopecia areata (AA) is an organ-specific autoimmune disease that affects the hair follicles of the scalp and the rest of the body causing hair loss. Due to the unpredictable course of AA and the different degrees of severity of hair loss, only a few well-designed clinical studies with a low number of patients are available. Also, there is no specific cure, but topical and systemic anti-inflammatory and immune system suppressant drugs are used for treatment.
View Article and Find Full Text PDF